Sterling Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Sterling Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.07K	Sell	932 -20	-2%	-$52	﹤0.01%	3134
2026 Q2	$2.54K	Buy	+952	New	+$2.35K	﹤0.01%	2922
2025 Q2	–	Sell	-685	Closed	-$754	–	3264
2025 Q1	$754	Sell	685 -740	-52%	-$1.06K	﹤0.01%	2894
2024 Q4	$2.45K	Buy	1,425 +1,292	+971%	+$3.11K	﹤0.01%	2726
2024 Q3	$330	Buy	+133	New	+$361	﹤0.01%	3010

Other funds holding ABOS

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

PWMAG

Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.71B AUM 23.29% 1-Year Est. Return

Clune & Associates Chicago, Illinois $654M AUM 13.19% 1-Year Est. Return

TFC Financial Management Boston, Massachusetts $893M AUM 15.25% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Sterling Capital Management's ABOS Position: Q3 2026 in Review

Sterling Capital Management reduced its Acumen Pharmaceuticals (ABOS) stake by 2.1% in Q3 2026, selling an estimated $52 and leaving 932 shares worth $2.07K. The position accounts for ﹤0.01% of the portfolio, ranked #3134.

Sterling Capital Management first reported a position in ABOS in Q3 2024 and has held it in 5 quarters since. The position peaked at $2.54K in Q2 2026. 10 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

Sterling Capital Management held 932 shares of Acumen Pharmaceuticals worth $2.07K as of Q3 2026.
Sterling Capital Management sold 20 Acumen Pharmaceuticals shares in Q3 2026, an estimated $52.
Acumen Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #3134 holding.
Sterling Capital Management first reported a position in Acumen Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
Sterling Capital Management's Acumen Pharmaceuticals position peaked at $2.54K in Q2 2026.
10 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.